3 March 2026
Nuformix plc
("Nuformix" or the "Company")
Result of Annual General Meeting
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that the Annual General Meeting of Nuformix plc was held earlier today and all resolutions put to shareholders were duly passed and approved by a show of hands. The proxies received ahead of the AGM, are reported below:
|
Resolution |
Ordinary/ Special |
For |
Against |
Total votes cast |
Withheld |
|||
|
No. of votes |
% |
No. of votes |
% |
|||||
|
1 |
To receive the annual report and accounts for the year ended 30 September 2025 |
Ordinary |
214,955,860 |
99.92% |
177,416 |
0.08% |
215,133,276 |
8,248,030 |
|
2 |
To approve the Annual Report on Remuneration |
Ordinary |
220,295,243 |
99.84% |
357,453 |
0.16% |
220,652,696 |
2,728,610 |
|
3 |
To re-appoint Daniel Gooding as a director |
Ordinary |
220,637,188 |
99.85% |
327,691 |
0.15% |
220,964,879 |
2,416,427 |
|
4 |
To re-appoint Julian Gilbert as a director |
Ordinary |
220,625,354 |
99.85% |
339,525 |
0.15% |
220,964,879 |
2,416,427 |
|
5 |
To re-appoint Madeleine Kennedy as a director |
Ordinary |
217,650,945 |
99.84% |
347,691 |
0.16% |
217,998,636 |
5,382,670 |
|
6 |
To re-appoint Kreston Reeves LLP as auditor |
Ordinary |
220,393,106 |
99.73% |
605,530 |
0.27% |
220,998,636 |
2,382,670 |
|
7 |
To authorise the Directors to determine the auditor's fees. |
Ordinary |
219,520,242 |
99.37% |
1,398,865 |
0.63% |
220,919,107 |
2,462,199 |
|
8 |
To authorise the Directors to allot shares. |
Ordinary |
209,386,402 |
97.46% |
5,449,425 |
2.54% |
214,835,827 |
8,545,479 |
|
9 |
To authorise the Directors to disapply pre-emption rights. |
Special |
211,574,241 |
98.46% |
3,311,586 |
1.54% |
214,885,827 |
8,495,479 |
|
10 |
To authorise the Company to purchase its own shares. |
Special |
213,681,044 |
95.98% |
8,956,820 |
4.02% |
222,637,864 |
743,442 |
|
11 |
To authorise calling of a general meeting on 14 clear days' notice. |
Special |
222,647,463 |
99.88% |
277,416 |
0.12% |
222,924,879 |
456,427 |
A vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.
The Company's issued share capital is 2,109,749,903 ordinary shares of £0.0005 each.
Enquiries:
|
Nuformix plc |
|
|
Dr Dan Gooding, Executive Director |
Via IFC Advisory |
|
CMC Markets |
|
|
Douglas Crippen |
+44 (0) 20 3003 8632 |
|
IFC Advisory Limited |
|
|
Tim Metcalfe Zach Cohen |
+44 (0) 20 3934 6632 nuformix@investor-focus.co.uk |
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.
For more information, please visit www.nuformix.com.